Heidelberg Pharma AG (XTER:HPHA) Cyclically Adjusted Revenue per Share: €0.23 (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:HPHA Heidelberg Pharma AG XTER:HPHA
51 GF Score
Price €2.60
GF Value €2.94
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Heidelberg Pharma AG Cyclically Adjusted Revenue per Share?

Heidelberg Pharma AG XTER:HPHA -1.89% 51 Cyclically Adjusted Revenue per Share is €0.23 as of May. 2026. GuruFocus rates XTER:HPHA with a GF Score™ of 51/100 and a GF Value™ of €2.94 (Modestly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Heidelberg Pharma AG's adjusted revenue per share for the three months ended in May. 2026 was €0.093. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.23 for the trailing ten years ended in May. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Heidelberg Pharma AG was -19.60% per year. The lowest was -29.60% per year. And the median was -23.80% per year.

As of today (2026-08-04), Heidelberg Pharma AG's current stock price is €2.60. Heidelberg Pharma AG's Cyclically Adjusted Revenue per Share for the quarter that ended in May. 2026 was €0.23. Heidelberg Pharma AG's Cyclically Adjusted PS Ratio of today is 11.30.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Heidelberg Pharma AG was 20.74. The lowest was 1.60. And the median was 8.66.


Heidelberg Pharma AG  (XTER:HPHA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Heidelberg Pharma AG's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2.60/0.23
=11.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Heidelberg Pharma AG was 20.74. The lowest was 1.60. And the median was 8.66.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Heidelberg Pharma AG Cyclically Adjusted Revenue per Share Related Terms


Heidelberg Pharma AG Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Heidelberg Pharma AG's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Heidelberg Pharma AG Cyclically Adjusted Revenue per Share Chart

Heidelberg Pharma AG Annual Data
Trend Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24 Nov25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.64 0.46 0.29 0.24 0.00

Heidelberg Pharma AG Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 0.22 0.00 0.22 0.23

XTER:HPHA vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Heidelberg Pharma AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heidelberg Pharma AG Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Heidelberg Pharma AG's Cyclically Adjusted PS Ratio falls into.


XTER:HPHA
51GF Score
Heidelberg Pharma AG XTER:HPHA
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Heidelberg Pharma AG Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Heidelberg Pharma AG's adjusted Revenue per Share data for the three months ended in May. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of May. 2026 (Change)*Current CPI (May. 2026)
=0.093/131.7855*131.7855
=0.093

Current CPI (May. 2026) = 131.7855.

Heidelberg Pharma AG Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201608 0.014 101.017 0.018
201611 0.020 100.517 0.026
201702 0.035 101.217 0.046
201705 0.028 101.817 0.036
201708 0.036 102.617 0.046
201711 0.032 102.117 0.041
201802 0.022 102.317 0.028
201805 0.047 103.917 0.060
201808 0.036 104.517 0.045
201811 0.022 104.217 0.028
201902 0.038 103.817 0.048
201905 0.094 105.418 0.118
201908 0.086 106.018 0.107
201911 0.040 105.318 0.050
202002 0.052 105.618 0.065
202005 0.052 106.018 0.065
202008 0.138 106.018 0.172
202011 0.032 105.018 0.040
202102 0.012 107.018 0.015
202105 0.014 108.170 0.017
202108 0.009 109.118 0.011
202111 0.018 110.173 0.022
202202 0.021 111.754 0.025
202205 0.328 115.760 0.373
202208 0.095 116.709 0.107
202211 0.060 119.872 0.066
202302 0.044 121.454 0.048
202305 0.050 122.824 0.054
202308 0.048 123.878 0.051
202311 0.069 123.668 0.074
202402 0.028 124.511 0.030
202405 0.060 125.776 0.063
202408 0.026 126.198 0.027
202411 0.033 126.409 0.034
202502 0.028 127.358 0.029
202505 0.003 128.412 0.003
202508 0.001 128.939 0.001
202511 0.000 129.361 0.000
202602 0.064 129.782 0.065
202605 0.093 131.786 0.093

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €0.23 mean?
Heidelberg Pharma AG (XTER:HPHA) has a Cyclically Adjusted Revenue per Share of €0.23 as of May. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Heidelberg Pharma AG and its competitors.
Is Heidelberg Pharma AG's Cyclically Adjusted Revenue per Share too high?
Heidelberg Pharma AG's current Cyclically Adjusted Revenue per Share is €0.23. Overall, Heidelberg Pharma AG has a GF Score™ of 51/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Heidelberg Pharma AG's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Heidelberg Pharma AG's Cyclically Adjusted Revenue per Share of €0.23 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Heidelberg Pharma AG and its competitors. Heidelberg Pharma AG's current Cyclically Adjusted Revenue per Share is €0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heidelberg Pharma AG stock overvalued right now?
Based on GuruFocus' analysis, Heidelberg Pharma AG (XTER:HPHA) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.94, compared to a current price of €2.60 — trading 11.6% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €0.23. Heidelberg Pharma AG's overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Heidelberg Pharma AG (XTER:HPHA), the current Cyclically Adjusted Revenue per Share is €0.23 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Heidelberg Pharma AG (XTER:HPHA) Overvalued in 2026?

Based on GuruFocus' analysis, Heidelberg Pharma AG stock appears to be undervalued. The current stock price of €2.60 is trading 11.6% below its estimated GF Value™ of €2.94. GuruFocus considers Heidelberg Pharma AG to be Modestly Undervalued.

Key valuation signals for XTER:HPHA:

  • Cyclically Adjusted Revenue per Share: €0.23
  • GF Value™: €2.94 vs. price of €2.60 (11.6% below fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the XTER:HPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Heidelberg Pharma AG Business Description

Other Exchanges 0QW5:UKHPHA:Austria
Address Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a biopharmaceutical company developing oncology treatments through antibody drug conjugates (ADCs), which combine antibody specificity with toxin potency to selectively target and kill cancer cells. The Company researches, develops, and produces these ADCs, and has built an ADC toolbox using various antibodies and payloads to address multiple cancers and overcome tumor resistance. Its activities focus on its proprietary ATAC technology based on Amanitin, the toxin of the death cap mushroom, leveraging its biological mechanism as a novel cancer therapy. The ATAC platform is used to develop proprietary ADC candidates and is also applied in collaborations with third parties.
51GF Score

Get the complete analysis for XTER:HPHA

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.60
Price
€2.94
GF Value